Italy is in talks with several pharmaceutical companies for the production of corona vaccines in the country.
These are vaccines that use so-called mRNA technology such as the vaccines from Pfizer / BioNTech and Moderna, which seem to be increasingly preferred by the European Union, writes the British business newspaper Financial Times.
The Italian government has had discussions with pharmacists Moderna, Novartis and ReiThera about the production. The latter two could then possibly produce the vaccine from CureVac, which is still under development.
In an mRNA vaccine, molecules transfer instructions to cells to make specific proteins. In response, people who are vaccinated make antibodies. Johnson & Johnson and AstraZeneca vaccines work differently. These are so-called vector vaccines. They are based on defused cold viruses, to which a piece of genetic code from the coronavirus has been added.
European Commission President Ursula von der Leyen announced last week that the EU will now focus mainly on mRNA corona vaccines when purchasing corona vaccines. At the time, she underlined that this does not mean that contracts will no longer be signed with producers who do not use the technology in the future.
Several European countries have restricted or discontinued the use of AstraZeneca after establishing an association with an infrequent side effect related to blood clots. For example, the AstraZeneca vaccine in the Netherlands is no longer given to people under the age of 60 as a precaution.
The rollout of the Johnson & Johnson vaccine has been delayed. In the United States, the vaccine is no longer used for the time being, while the American Center for Disease Prevention (CDC) investigates a possible link between the vaccine and rare cases of blood clots.